TD Cowen Initiates Coverage On Braveheart Bio with Buy Rating

Benzinga Newsdesk www.benzinga.com Neutral 68.8%

Neg 0% Neu 68.8% Pos 0%

TD Cowen analyst Tyler Van Buren initiates coverage on Braveheart Bio (NASDAQ:BRVE) with a Buy rating.

Comments

No comments yet. Be the first!